Abstract Purpose: Cyclin D1 is found on 11q13, which is a region frequently amplified in several tumor types. The CCND1 locus gives rise to at least two protein isoforms of D1 (D1a and D1b). A common G/A polymorphism (G/A870) is thought to influence the expression levels of D1a and D1b. D1b has been suggested to be increased in the presence of the A allele and more oncogenic than D1a. Furthermore, the A allele has been reported to correlate with increased risk of carcinoma in several tumor types, suggesting that this polymorphism and D1b are important in tumor progression. However, contradictory data about the polymorphism, D1variant expression, and correlation with survival have been reported. We explored the relationship between gene amplification, G/A870 genotype, D1a and D1b expression, and overall survival in esophageal adenocarcinoma and non^small cell lung cancer. Experimental Design: DNA and RNA were isolated from 54 esophageal adenocarcinoma samples and 89 non^small cell lung cancer samples and were analyzed for gene amplification, genotype at the polymorphism, gene expression, and association with overall survival. Results: The D1 variant expression did not correlate with amplification, genotype, or overall survival in either tumor type. The total D1expression correlated with decreased patient survival. Several other genes on 11q13 also seem to be overexpressed and correlated with decreased survival. Conclusions: We report that the G/A870 polymorphism does not correlate with patient survival, or with D1a or D1b expression. However, the total D1 expression and the expression of several other genes on 11q13 seem to be associated with esophageal adenocarcinoma patient survival.
Genomic instability resulting in DNA amplification, rearrangements, or deletions is a common mechanism by which tumors modulate gene expression and acquire invasive and metastatic potential (1, 2) . The chromosomal band 11q13 has been found to be amplified or rearranged in a wide variety of carcinomas, including breast, head and neck, and bladder, and this is often associated with poor prognosis (3 -6) . The 11q13 amplicon core is a gene-rich region containing at least 10 genes. However, despite reports on the overexpression of other genes in the region (4, 7) , the most likely tumorigenic driver at this locus is still thought to be CCND1, which encodes cyclin D1.
Cyclin D1 was identified in 1991 as a proto-oncogene, and its role in cell cycle progression was established soon after. Cyclin D1 is a highly regulated factor, induced by mitogenic signals to transition cells from the quiescent G 1 phase to the proliferative S phase of the cell cycle. Once induced, it binds and activates the cyclin dependent kinases 4 and 6, which hyperphosphorylates the Rb protein to release the E2F transcription factor necessary for the expression of S-phase genes.
In 1995, a frequent G/A single-nucleotide polymorphism (SNP) was identified in the CCND1 gene (8) . This G/A polymorphism (G/A870) occurs at the exon 4 splice-donor site and, although it does not alter the amino acid encoded, it is hypothesized to affect splicing at the exon 4/intron 4 boundary. The G allele represents a more conserved consensus splicedonor site than the A allele, which may not be recognized as efficiently (9) . The result is reduced splicing at the exon 4/ intron 4 boundary and the expression of a truncated protein due to an intronic, in-frame TGA stop codon (Fig. 1) . Consequently, the COOH-terminal domain of the resulting cyclin D1 variant, cyclin D1b, which does not encode the fifth and final exon, lacks the residues required for nuclear export and has been shown to be constitutively nuclear in localization (10, 11) . Furthermore, cyclin D1b showed increased transforming capability compared with the fulllength D1 variant, D1a, and therefore may be a more potent oncogene.
Whereas both homozygous A and G genotypes can give rise to cyclin D1a and D1b transcripts, it is generally thought that the A allele results in the increased expression of cyclin D1b compared with the G allele. However, this belief is derived from only two reports (8, 12 ) on a limited number of nonsmall-cell lung cancer (NSCLC), and head and neck cancer samples. Furthermore, in a recent review of CCND1 in NSCLC, data is presented that seems to contradict the original NSCLC report (13) . In addition, one study on lymphoma and leukemia actually found that the G allele, not the A, may result in increased D1b expression (14) . Thus, although some differences in alternative splicing may be tissue specific, the association between the A/G870 SNP and cyclin D1, D1a, and D1b expression remains unclear.
Independent of cyclin D1 expression levels, several studies have identified a correlation between the A/A and A/G genotypes, and an increased risk of developing cancer or decreased overall survival in various tumor types, including breast, colon, head and neck, lung, and esophageal squamous cell carcinoma. As with the gene expression studies, the results among different studies are not entirely consistent (12, 13, 15 -21) but, in general, there seems to be an association of the A allele with cancer risk and progression. Because cyclin D1b has increased oncogenicity and is believed to be preferentially expressed from the polymorphic A allele, the relationship between SNP genotype, variant expression, and overall survival needs to be clarified.
In this study, we have quantitatively analyzed DNA and RNA isolated from a large series of primary esophageal adenocarcinoma (EAC) and NSCLC tissues. We examine the relationships among the CCND1 G/A polymorphism; 11q13 amplification; cyclin D1, D1a, or D1b expression; and overall survival. We report that amplification at 11q13 has no allele bias, that the G/A870 SNP does not correlate with the expression of cyclin D1a or D1b, and that the G/A870 genotype does not correlate with patient survival. The overall expression of cyclin D1 may be associated with survival in EAC but not in NSCLC, and the expression of individual cyclin D1 variants does not seem to be prognostic. Finally, in EAC, other genes in the 11q13 amplicon may be important drivers of tumor progression in addition to CCND1.
Materials and Methods
Patients and tissues. EAC and lung carcinoma specimens were obtained from patients treated at the University of Pittsburgh Medical Center. All patients provided informed consent, and the research was approved by the appropriate International Review Boards. Patient characteristics are shown in Table 1 . The tumors were snap frozen in liquid nitrogen and embedded for sectioning on a cryostat. H&E slides from each specimen underwent a pathologic review to identify those with >70% tumor. Twenty to sixty 5-Amol/L sections were then cut for nucleic acid isolation. Fifty-four EAC samples were analyzed for genotyping, but the survival information is a reflection of 39 patients. The survival data is a reflection of 68 of 89 patients for lung carcinoma specimens (Table 1) .
Nucleic acid isolation. The genomic DNA was isolated from tumor tissue with the use of the QiaAmp DNA Mini Kit (Qiagen) according to the manufacturer's protocols. Similarly, the total RNA was isolated with the use of the Stratagene RNA Isolation Kit (Stratagene) according to the Fig. 1 . Cyclin D1splice variants. Cyclin D1a encodes all 5 exons and a 3 ¶ untranslated region (UTR) with two putative polyadenylation signals about 300 and 3,000 bases downstream of theTGA stop codon. D1b encodes exons 1to 4 and part of intron 4 with its 3 ¶ untranslated region found in intron 4. Similar to D1a, the cyclin D1b 3 ¶ untranslated region has two potential polyadenylation sites about 300 and 3,000 bases downstream of the stop codon. The expression of D1a or D1b is hypothesized to be determined by the G/A polymorphism at nucleotide 870, the last nucleotide of exon 4, and the recognition of the exon 4/intron 4 boundary.
Translational Relevance
Cyclin D1is an oncogene that is frequently amplified and overexpressed in many tumor types. It has been suggested that cyclin D1amplification, expression, and genotype at a specific single-nucleotide polymorphism (G/A870) may be associated with cancer risk and patient outcome. Cyclin D1 genotype has also been associated with the expression of two different cyclin D1 isoforms: D1a and D1b. However, the clinical relevance of cyclin D1 amplification, genotype, and D1a and D1b expression has never been systematically explored. We find that the genotype of cyclin D1 does not affect isoform expression and does not seem to be a marker of prognosis. The association of the G/A870 singlenucleotide polymorphism with cancer risk does not, therefore, seem to be a result of increased cyclin D1b expression. The total cyclin D1 expression does, however, seem to be associated with survival in esophageal cancer but not in lung cancer. In addition, the expression of several other genes at the 11q13 locus seems to correlate with amplification and decreased patient survival. The examination of the expression of several genes in this chromosomal region may therefore be more effective as prognostic markers than cyclin D1expression or genotype alone.
manufacturer's protocols. DNA and RNA quantity and purity were determined by UV absorbance. DNA quality was assessed by gel electrophoresis, and the total RNA integrity was determined with the use of Agilent Bioanalyzer RNA Nano chips. No samples were used unless the RNA integrity number was >6.0.
CCND1 genotype and allele-specific copy number analysis. DNA was analyzed by RFLP-PCR as previously described (8) . Briefly, 1-ng genomic DNA was amplified by PCR under the following conditions: 10-min initial denaturation at 95jC followed by 40 cycles of denaturation at 95jC for 30 s, annealing at 55jC for 30 s, elongation at 72jC for 30 s, and ending with a final extension at 72jC for 7 min. The 167-bp PCR products were digested for 16 h at 37jC, followed by 20 min at 65jC with 1 units of the ScrFI restriction endonuclease (New England Biolabs), which recognizes the sequence 5-CCNGG-3 when the G allele is present but not the polymorphic A allele. The digested PCR products were then analyzed by electrophoresis on ethidium bromide -stained 10% Tris-borate EDTA criterion gels (Bio-Rad). Samples with the G/G genotype produced two bands (146 and 21 bp); the A/A genotype produced one band (167 bp) and the G/A genotype produced three bands (167, 146, and 21 bp). The genotype was determined by reference to control samples.
Genotypes of all samples were also confirmed by real-time PCR with the use of the Applied Biosystems TaqMan SNP Genotyping Assay (assay #C_744725_1) and the TaqMan Universal PCR Master Mix (Applied Biosystems) according to the manufacturer's protocols. The assays are designed with a single set of primers and two dual-labeled probes identical in sequence, except for a single-nucleotide change (G or A), labeled with either the FAM (G allele) or VIC (A allele) flourophore. Real-time PCR and end-point allelic discrimination reactions were done on the ABI 7900HT PCR machine. Each sample was analyzed in two separate experiments, each in triplicate (n = 6). The genotype was determined by reference to control samples.
The allele-specific CCND1 copy number was determined with the use of a variation of Quantitative Microsatellite Analysis (QuMa) as previously described (22) . The PCR loci for the microsatellite reference pool included D4S1605, D5S478, D12S1699, D14S988, D21S1904, and D22S922, and used previously published primer sequences (23) along with a FAM/BHQ dual-labeled T (GT) 10 probe.
Briefly, the Ct values for the FAM (G allele) and VIC (A allele) probes used in the TaqMan genotyping study were averaged separately for each sample, and the Ct for the pooled microsatellite reference was subtracted to obtain a yCt value [yCt sample = Ct FAM or VIC -Ct microsatellite reference ]. The FAM and VIC yCt values were also determined for 16 heterozygous normal lung samples, which served as the calibrator (yCt calibrator ) for copy number calculations. Each sample (including controls) was analyzed in two separate experiments, each in triplicate (n = 6 for each mean Ct value). The yyCt was then determined by subtracting the yCt calibrator from the yCt sample for each sample and each allele [for example, yyCt (G allele) = yCt FAM Sample -mean yCt FAM Calibrator ]. The relative DNA copy number for each allele at the CCND1 locus was then calculated as 2 -(yyCt) . Under this methods, the copy number estimate for a homozygote should be f2 whereas for a heterozygote, it should be 1.
Ninety-five percent confidence intervals were then calculated for each allele with the use of the SD of the 16 FAM and 16 VIC yCt values observed in the controls. The confidence intervals were applied separately to heterozygous and homozygous cases to determine statistically significant differences from one or two copies, respectively.
Gene expression analysis by reverse transcription real-time PCR. Two micrograms of the total RNA extracted from the same samples analyzed for genotyping was reverse transcribed in 100 AL reactions with 1Â PCR buffer, 7.5 mmol/L MgCl 2 , 1mmol/L deoxynucleotide triphosphate, 500 Amol/L random hexamers, 0.8 units of RNase block (Stratagene), and 0.1 units of Moloney murine leukemia virus reverse transcriptase. The reaction was carried out with the following protocol: 10 min at 25jC, 40 min at 48jC, and 5 min at 95jC. The cDNA was diluted 4-fold and was examined for expression of total cyclin D1, cyclin D1a, and cyclin D1b in both EAC and NSCLC samples, and for expression of TAOS1, TAOS2, and MYEOV in the EAC samples only. All gene expression was normalized to the endogenous control gene hglucuronidase. The relative expression was determined through the yCt methods described previously (24) .
The total D1 expression was analyzed with the use of Applied Biosystems Gene Expression Assays-on-Demand (Applied Biosystems; assay # Hs00277039_m1) with primers and probes that span exon 2 to 3. Cyclin D1a-specific and D1b-specific expression were examined with the use of a common dual-labeled probe in exon 4 (5 ¶-FAM-TTCCTCTCCAGAGTGATCAAGTGTGACCC-BHQ-3 ¶) and the following PCR primers: (D1a-forward 5 ¶-GTCCTACTACCGCCTCACACG-3 ¶, D1b-forward 5 ¶-TGAGGAGCCCCAACAACTTC-3 ¶, D1a-reverse 5 ¶-TTCGATCTGCTCCTGGCAG-3 ¶, and D1b-reverse 5 ¶-CCTGGGACAT-CACCCTCACTTA-3 ¶). The sequences for the TAOS1 PCR primers and probe were previously published (23) . The MYEOV expression was analyzed with the use of Applied Biosystems Gene Expression Assays-on-Demand (assay # Hs00371084_m1). TAOS2 was analyzed with the use of the following oligonucleotides: forward primer 5 ¶-GAGCCAAAGACATCGGAATCTG-3 ¶, reverse primer 5 ¶-TGAAGGAGAT-CACGAAGGCAT-3 ¶, and a dual-labeled FAM/BHQ probe 5 ¶-CTCA-GAGGCATTGGGAAGCTTGCTGT-3 ¶.
All gene quantitative-PCR assays were done with the use of the Universal TaqMan PCR Master Mix (Applied Biosystems) with the appropriate primers and probes, and 2 AL of diluted cDNA under the following conditions:10-min initial denaturation at 95jC followed by 45 cycles of denaturation at 95jC for 30 s and annealing at 60jC for 1 min on an ABI 7900HT instrument (Applied Biosystems). Each sample was analyzed in two separate experiments, each in triplicate (n = 6) for each gene and normalized to h-glucuronidase. The average Ct was used to calculate the gene expression.
Statistical analyses. The association of genotype (AA, AG, or GG) and 11q13 amplification (positive/negative) with patient survival was explored with the use of a Kaplan-Meier overall survival curves and logrank tests. The associations of genotype with disease stage (I/II versus III/IV) and lymph node status (positive or negative) were determined through a m 2 test. ANOVA was used to assess the association between 11q13 amplification and cyclin D1, cyclin D1a, cyclin D1b, MYEOV, TAOS1, and TAOS2 expression as well as between genotype and D1, D1a, and D1b expression. The association of gene expression with overall survival was estimated with Cox proportional hazards regression coefficients and by generating Kaplan-Meier survival curves based on a median split of gene expression.
Results
CCND1 genotype, amplification, and survival in 54 primary EAC tumors. The genotype of CCND1 at the G/A870 SNP was examined in 54 EAC primary tumors. RFLP-PCR revealed 22 homozygous genotypes (8 A/A, 14 G/G) and 32 heterozygous (G/A) genotypes (Fig. 2) , and this was confirmed by TaqMan allelic discrimination assays. An allele-specific copy number analysis identified amplification in 13 (24%) EAC samples, with monoallelic amplification in 12 of the 13 cases. Three to 16 copies of the A allele were observed in 3 A/A and 3 G/A samples. Three to 19 copies of the G allele were observed in 5 G/G and 2 G/A samples. A single G/A sample showed amplification (4-5 copies) of both the G and the A alleles. Neither CCND1 genotype nor amplification correlated with survival, age at onset, tumor stage, or node status (data not shown).
Association of cyclin D1, D1a, and D1b expression with genotype and survival in EAC. Cyclin D1, D1a, and D1b mRNA expression was examined by real-time TaqMan PCR in RNA extracted from a subset of the same EAC samples (45 EAC) analyzed for genotyping. The CCND1 locus is amplified in 12 of the 45 EAC examined for D1 expression. D1a and D1b expression did not correlate with amplification (two-tailed Student's t test assuming equal variance, P = 0.11and P = 0.37, respectively) but the total D1 expression was statistically significant (P = 0.035; Fig. 3A) . Neither D1a nor D1b expression correlated with genotype (Fig. 3B) . Interestingly, high expression of total cyclin D1 seems to correlate with decreased survival (Cox regression, P = 0.045; log rank, P = 0.077 based on a median split), but neither D1a nor D1b expression individually reached statistical significance for association with survival (Cox regression, P = 0.24 and P = 0.13, respectively; Fig. 3C ).
CCND1 genotype, amplification, and survival in 89 primary NSCLC tumors. The CCND1 G/A870 SNP genotype was examined in 52 adenocarcinomas (AC) and 37 squamous cell lung carcinomas (SCC). RFLP-PCR and SNP genotyping by realtime PCR revealed 44 homozygous genotypes (6 A/A and 15 G/G in the AC; 10 A/A and 13 G/G in the SCC) and 45 (31 AC and 14 SCC) heterozygous G/A genotypes (data not shown). CCND1 allele-specific copy number changes determined by QuMa showed monoallelic gene amplification (>2 copies) in 17 (19%) NSCLC samples. Three to 22 copies of the A allele were observed in 6 A/A (3 AC and 3 SCC) and 2 G/A (both AC) samples. Three to 12 copies of the G allele were observed in 9 G/G (4 AC and 5 SCC). No amplifications of the G allele were observed in the heterozygous G/A genotype. Similar to EAC, neither CCND1 genotype nor amplification correlated with survival, early age at onset, tumor stage, or node status (data not shown).
CCND1 amplification, G/A870 genotype, and expression of cyclin D1a and D1b in NSCLC. Cyclin D1, D1a, and D1b mRNA expression was examined in a subset of the same NSCLC samples (40 AC and 29 SCC) analyzed for genotyping. The CCND1 locus is amplified in 12 of these 69 NSCLC samples, but increased cyclin D1 was not observed in samples with amplification (Fig. 4A) . Similar to results in EAC, neither D1a nor D1b expression correlated with genotype (Fig. 4B) . Furthermore, the total cyclin D1, D1a, and D1b expression did not significantly correlate with survival (Fig. 4C) .
Other genes in the 11q13 amplicon are overexpressed in EAC and correlate with survival. The 11q13 amplicon is a gene-rich region. Previously published reports have shown TAOS1, TAOS2, and MYEOV overexpression in breast, head and neck, and esophageal squamous cell carcinoma samples with genomic amplification (23, 25, 26) . Therefore, we analyzed the expression of TAOS1, TAOS2, and MYEOV in the same 45 EAC RNAs examined for CCND1 expression. The TAOS1 and MYEOV expressions were statistically correlated with amplification (two-tailed Student's t test assuming equal variance, P = 0.0061 and P = 0.012, respectively) whereas TAOS2 was borderline (P = 0.074; Fig. 5A ). Interestingly, neither TAOS1 nor MYEOV expression correlated significantly with survival none of these SNPs result in amino acid substitutions, the G/A transition at nucleotide 870 is thought to affect CCND1 expression because it occurs at the final intron/exon boundary and may alter the recognition of the exon 4 splice-donor site (9) . It has been reported that the A allele at this SNP may be correlated with both increased risk of carcinoma and poor patient outcome although these reports are somewhat inconsistent. However, the literature also provides a possible biological rationale for an association of the A allele with clinical end points. It has been reported that the A allele may Fig. 4 . CCND1 expression does not correlate with amplification, genotype, or survival in NSCLC. RNA isolated from a subset of the same primary tumors analyzed for genotyping were examined for total D1, D1a, and D1b expression. CCND1 did not correlate with amplification (A), genotype (B), or survival (C) in NSCLC. In C, low-expression and high-expression groups were selected based on a median split of expression observed in all samples. result in the increased expression of a cyclin D1 variant (cyclin D1b) with increased oncogenic potential. Whereas cyclin D1a (the full-length isoform typically referred to as cyclin D1) encodes all 5 exons, D1b is homologous through exon 4 but lacks the fifth and final exon and, instead, contains part of intron 4 and a different 3 ¶ untranslated region (Fig. 1) . Theoretically, the AA genotype and/or amplification of an A allele in tumors would result in higher expression of cyclin D1b, thus increasing cancer risk and resulting in a more aggressive disease. So far, however, these hypotheses have never been fully examined.
Cyclin D1 variant expression and association with the G/A870 polymorphism was originally examined in nine heterozygous NSCLC samples. These data indicated that D1a was preferentially expressed from the G allele and D1b from the A allele (8) . Subsequently, a similar finding was reported in three head and neck squamous cell carcinoma samples (12) . However, a study in lymphoma found that the A allele gave rise to the D1a transcript and, conversely, the G allele was the major source of D1b expression (14) . These contradictory results could suggest tissue-specific or tumor-type differences, but in a 2007 review article, an analysis of 48 NSCLC failed to show a correlation between the genotype and D1 isoform expression, and the data supporting this was not shown, leaving questions about the relationship between the G/A870 SNP and D1a or D1b expression (13) .
In this study, we analyzed genotype, allele-specific amplification, cyclin D1 variant expression levels, and patient survival in 54 EAC and 89 NSCLC specimens. We found that CCND1 was amplified in 24% of EAC samples and 19% of NSCLC samples, but no allele-specific amplification bias was observed. Furthermore, we did not see any association of genotype with patient survival in either tumor type. We observed that, for the most part, samples with amplified CCND1 exhibited increased total cyclin D1 mRNA expression, but neither D1a nor D1b levels individually were significantly elevated in amplified samples. Furthermore, neither D1a nor D1b expression correlated with genotype or with survival. Interestingly, increased total D1 expression did correlate with survival in EAC but not in NSCLC. This may suggest a tissue-specific effect of CCND1 expression. It may also be that total cyclin D1 expression is more important in terms of tumor development and progression than either of the individual variants alone.
Currently, studies in multiple tumor types have examined the effect of the G/A870 polymorphism on cancer risk and survival. Whereas several studies in breast (16) , head and neck (19) , and colorectal cancers (17) have implicated the A/A or A/G genotype with increased risk of carcinoma, other studies in the very same tumor types have implicated the G/G genotype with increased risk of carcinoma (12, 18) or have found no effect of the polymorphism (15, 20) . In EAC, the A/A genotype was associated with increased risk of carcinoma in one study (27) but not in another (28) , and increased D1 protein correlated with poor overall survival of patients (29) . Although we cannot assess cancer risk in our study, we were unable to find a correlation between genotype and survival. Furthermore, if one allele provides an advantage to the tumor, then one may anticipate an allele-specific bias in the amplification of the CCND1 locus in tumors, but none was observed. The discrepancy in results among different studies could be due to several factors. First, a disparity in allelic distribution exists among ethnic populations (11) , suggesting that the polymorphism affects the populations differently, and large, multiethnic studies are needed to investigate the effect of the polymorphic allele on survival (9) . Given the near-equal frequency of the polymorphism (f42% A and 58% G), it is difficult for this SNP alone to be an effective predictor of a complex multistage disease. In addition, the G/A870 SNP may be in linkage disequilibrium with a C/G SNP at position 1722 in D1 because patients with A870 most likely carry C1722 as well (12) . It is possible that the G/A870 polymorphism is an effective predictor of prognosis or risk only when additional factors, such as a second polymorphism, are taken into account (9, 12, 16) .
Another possible reason for the lack of consensus in studies is that we may not have a complete picture of the regulation of the transcripts generated from the CCND1 locus. Previously, Northern blot analysis of CCND1 revealed two transcripts: a 4.2 kb to 4.8 kb transcript and a 1.3 kb to 1.7 kb transcript. Cloning and sequencing of the transcripts revealed that, Fig. 5 . Expression of other genes on 11q13 amplicon correlate with amplification or survival in EAC. The MYEOV,TAOS1, and TAOS2 expressions were analyzed in the sample RNA for total D1, D1a, and D1b expression. A, MYEOV and TAOS1correlate with amplification butTAOS2 did not. B, although the high expression of all genes trended toward decreased survival, only highTAOS2 expression correlated significantly with decreased survival. Low-expression and high-expression groups were selected based on a median split of expression observed in all samples.
although they both contained exons 1 to 5, the shorter transcript terminated 0.2 kb downstream of the stop codon (30, 31) whereas the longer transcript terminated f3,000 bp downstream, thus accounting for the difference observed on Northern blots. Recently, a similar, short cyclin D1a transcript associated with longer mRNA half-life, increased proliferation, and shorter length of patient survival was reported in mantle cell lymphoma (32) . Although this transcript was polyadenylated, it was suggested that no polyadenylation-like signals could be found (8, 32) . However, the examination of exon 5 does, in fact, reveal an ''AATAAT'' polyadenylation-like signal f300 bases downstream of the TGA stop codon (Fig. 1) . Thus, it seems likely that the transcript observed in mantle cell lymphoma may be a naturally occurring variant. Given its apparent difference in half-life and its effect on proliferation and survival, this short version of the CCND1a deserves further investigation. In addition, the examination of intron 4 revealed 2 polyadenylation-like signals: one f300 bases (''AATAAA'') after the stop codon used in cyclin D1b and the other f3,000 bases (''TATAAA'') later (Fig. 1) . Similar to the Northern blots of D1a, two transcripts have also been reported for D1b, differing by f3 kb in size (8) . Thus, both cyclin D1a and D1b seem to have long and short transcripts that differ in their 3 ¶ untranslated regions, underscoring the complexity of D1a and D1b gene expression and possible function.
It has been reported that D1 is overexpressed in a wide variety of cancers, but overexpression alone does not result in cellular transformation or tumorigenesis (33 -36) . It has been assumed that cyclin D1 overexpression promotes tumorigenesis through its role in proliferation (37, 38) . Although it is clearly involved in cell cycle progression, studies examining tumor samples with increased D1 expression did not find increased cell cycle activity (hyperphosphorylation of the Rb protein, increased proliferation) in tumor samples (39, 40) . Thus, it is likely that cyclin D1 may have other, less understood roles in cell function and may exert its actions through cyclindependent kinase -independent activities, as shown by D1 mutants incapable of activating cyclin-dependent kinase 4/6 (41) . Furthermore, recent data suggest that D1a and D1b may have differing roles in cell cycle function. D1b may have cell cycle -independent activities (36) . Additionally, D1b has been shown to have an inverse role from D1a or no activity at all in the cell cycle (42, 43) . Understanding D1a and D1b activities is important to understanding their role in tumorigenesis and to D1 serving as a useful prognostic or therapeutic target. Current cyclin-dependent kinase 4/6 small-molecule inhibitors that target tumor cells with kinase activity and wild-type retinoblastoma may not be useful in patients with higher expression of D1b if D1b acts in an inverse manner to D1a (9, 44) .
Finally, the effect of 11q13 amplification may not be limited to the expression of a single gene. The 11q13 amplicon core contains more than 10 known genes (including MYEOV, TAOS1, TAOS2, FGF3, and FGF4), with CCND1 being the most consistently studied. Recently, however, TAOS1 expression was found to be more dependent on copy number than CCND1 in oral squamous cell carcinoma cell lines (23) . In addition, MYEOV has been shown to be coamplified with CCND1 (25, 26) . We examined the expression of these two genes and found that both correlated with 11q13 amplification but did not correlate with survival. We also examined the expression of TAOS2 and were surprised to find that, although it did not correlate with amplification, high expression correlated with decreased overall survival. Thus, TAOS1 and MYEOV seem to be regulated by gene copy number whereas TAOS2 expression is not. This is similar to findings in oral squamous cell carcinoma, in which TAOS2 was reported to be the only gene that was consistently overexpressed in samples without 11q13 amplification, suggesting other mechanisms of regulation of expression (23) . Although the functions of MYEOV, TAOS1, and TAOS2 are currently unknown, their correlation with amplification or survival suggests that they, along with CCND1, may play a role in EAC tumorigenesis.
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